Opus Genetics IRD
NASDAQ IRD
$4.11 +0.10 (+2.62%)
At close: Oct 21, 2026 · 4:00 PM EDT

Opus Genetics (IRD) Preferred Stock Liabilities (2026)

Updated

Opus Genetics (IRD) posted Preferred Stock Liabilities of $24.74 million for Q1 2026.

Analysis

Opus Genetics (IRD) Preferred Stock Liabilities (2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn -
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn -
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn -
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn -
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn -
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn -
10 Opus Genetics 391.96 Mn 167.24 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2026 24.74 Mn
API Access

Opus Genetics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=IRD&period=max&api_key=YOUR_API_KEY